Antimicrobial Resistance Challenges in the DoD

1
Antimicrobial Resistance Challenges in the DoD

• CDR Clara Witt, USPHS
• Deputy Director, Antimicrobial Resistance,
  Zoonotic and Vectorborne Diseases
• DoD GEIS

2
Picture K. Lounatmaa, WHO
Bacteria manifesting drug resistance in culture
3
IOM Forum on Emerging InfectionsAntimicrobial
Resistance (July 1997)

• Everything we do to expose bacteria to drugs
  (I,e. prescribe for infections, develop new
  drugs) gives bacteria the opportunity to develop
  resistance.
• Therefore in combating antimicrobial resistance
  as a public health and clinical threat, we need
  to focus on
• controlling or slowing its emergence
• preventing its spread (containment)

4
The US Interagency Task Force Action Plan to
Combat Antimicrobial Resistance

• January 2001
• Federal blueprint for addressing the emerging
  threat of antimicrobial resistance (AR)
• CDC, FDA, NIH (Co-chairs), AHRQ, CMS, HRSA, USDA,
  DVA, EPA, USAID and DoD
• Part 1 Domestic, Part 2 International
• Annual Reports inventory of projects/activities
  undertaken by Agencies to implement the plan.

5
(No Transcript)
6
US Interagency Task Force Action Plan to Combat
Antimicrobial Resistance

• Surveillance (20 action items, 2 priority)
• Develop and implement a coordinated national plan
  for monitoring AR
• Ensure the availability of reliable drug
  susceptibility data
• Track patterns of antimicrobial drug use
• Monitor AR in agricultural settings

7
US Interagency Task Force Action Plan to Combat
Antimicrobial Resistance

• Prevention and Control (45 action items, 5
  priority)
• Extend the useful life of antimicrobials through
  
• policies that discourage overuse and misuse
• Improve diagnostic testing practices
• Prevent infection transmission through improved
  infection-control methods and use of vaccines

8
US Interagency Task Force Action Plan to Combat
Antimicrobial Resistance

• Research (11 action items, 3 priority)
• Basic and clinical to provide the knowledge
  necessary to develop appropriate responses to AR
  in hospitals, communities, farms and food supply
• Microbe physiology, ecology, genetics, and
  mechanisms of resistance
• Augment existing research
• Translate into clinically useful products, novel
  approaches to detecting, preventing and treating
  AR infections

9
US Interagency Task Force Action Plan to Combat
Antimicrobial Resistance

• Product Development (6 action items, 2 priority)
  
• Focus on current and projected gaps in the
  arsenal of
• Antimicrobial drugs
• Vaccines
• Diagnostics

10
Picture L. Stannard, WHO
Salmonella
11
(No Transcript)
12
Task Force Action Plan Applied to DoD

• Surveillance Defining/updating guidelines for
  empiric (syndromic) treatment and standard
  treatment guidelines reassessing DoD and MTF
  formulary assuring drug supply is appropriate
  for need identifying need for implementation of
  infection control measures monitoring impact of
  intervention to improve antimicrobial use and to
  control the emergence and spread of infection.

13
Task Force Action Plan Applied to DoD

• Prevention and Control - Promote the appropriate
  use of antimicrobial drugs and prevent the
  transmission of infections (whether
  drug-resistant or not)
• Research - Develop basic and clinical knowledge
  and tools for appropriately addressing AR
  emergence and spread.
• Product Development - Meet need for new classes
  of antimicrobial agents able to kill otherwise
  resistant organisms, vaccines and anti-infective
  devices to prevent infections, and better
  diagnostic tools to aid in appropriate use of
  therapeutics.

14
(No Transcript)
15
(No Transcript)
16
(No Transcript)
17
Picture A. Pasieka
Streptococcus bacteria
18
Source Pfizer Inc.